Otsuka Pharmaceutical
Otsuka Inks $613M Deal for Cantargia’s Autoimmune Antibodies
Otsuka Pharmaceutical; Cantargia; autoimmune diseases; IL1RAP antibodies; CAN10; biotech deal; hidradenitis suppurativa; systemic sclerosis; milestone payments; global commercialization